Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 4 Jun 2026
- Closes
- 30 Sept 2026, 23:59 UTC
- Value
- USD 2,000,000
- Reference
- RFA-DK-27-109
- Location
- United States
- Sector
- Healthcare & Pharma
Details
This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). The purpose of CaRe-T1D is to support innovative, discovery and mechanistic research through the study of human cardiovascular (CV) tissue. This research seeks to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and ultimately guide the development of therapies to treat this major cause of morbidity and mortality for individuals with type 1 diabetes. To achieve these goals, the Resource Center will expand the CaRe-T1D biorepository of human CV tissue, further develop the data commons for data sharing and for artificial intelligence (AI) tools, coordinate the research activities of the investigative teams in the CaRe-T1D consortium, and make CaRe-T1D resources accessible to the broader research community. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Only the following applicant is eligible to apply for this single source funding: University of Florida. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Estimated total programme funding: USD 2000000
Expected number of awards: 1
CFDA number(s): 93.233
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 408 notices from National Institutes of Health, going back to May 2023 — 390 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 399 open Healthcare & Pharma tenders in United States. This one closes in 6 days.
More from this buyer
- Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)· closes 10 Nov
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)· closes 10 Nov
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)· closes 17 Apr
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)· closes 10 Nov
- Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)· closes 25 May
Similar Healthcare & Pharma tenders
- Breathing Apparatus — Safety and Rescue Equipment· closes 26 Oct
- Advancing bio-printing of living cells for regenerative medicine· closes 22 Sept
- Development of cell-free protein synthesis platforms for discovery and/or production of biologicals· closes 13 Apr
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential· closes 13 Apr
- Development of innovative antimicrobials against pathogens resistant to antimicrobials· closes 13 Apr
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- ФІЛІЯ «ЛОКОМОТИВНА КОМПАНІЯ» АКЦІОНЕРНОГО ТОВАРИСТВА «УКРАЇНСЬКА ЗАЛІЗНИЦЯ» invites bids for МилоФІЛІЯ «ЛОКОМОТИВНА КОМПАНІЯ» АКЦІОНЕРНОГО ТОВАРИСТВА «УКРАЇНСЬКА ЗАЛІЗНИЦЯ» · Ukraine
- Renovation of electrical services in Ward No 1 and main casualty area at Dr BSA Hospital Rohini DelhiPublic Works Department · CE/SE/B2-B24 · EE/B243(N) · India
- Repair work of road Patch by Hot Mix Plant From Chandan Medical Store to Transformer Ward63 Under Zone02Kanpur Municipal Corporation, Kanpur, UP · India
- Procurement of Cytotoxic Drugs used in Hormonal, Immuno, Supportive and ChemotherapyHEALTH · Mauritius
- Procurement of Cytotoxic Drugs Used in Targeted Therapy (Annual Requirements) Mhpq/Pharm/2026-2027/Q66 OIBHEALTH · Mauritius
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →